Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
UNKNOWN
NCT06780579

Expanded Access for Bulevirtide

Sponsor: Gilead Sciences

View on ClinicalTrials.gov

Summary

The goal of this study is to provide access to bulevirtide (BLV (GS-4438), Hepcludex®) to eligible participants with chronic hepatitis delta virus infection (CHD).

Official title: Expanded Access Treatment Protocol for Bulevirtide

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

EXPANDED_ACCESS

Enrollment

Not specified

Start Date

Not specified

Completion Date

Not specified

Last Updated

2026-06-12

Healthy Volunteers

Not specified

Interventions

DRUG

Bulevirtide

10 mg BLV will be administered via subcutaneous injection